secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001213900-25-067791
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio Phase 2 XPro trial misses primary endpoint; positive subpopulation data at AAIC
--------------------------------------------------------------------------------

- Primary endpoint not met in mITT group; 208 early-AD participants with inflammation biomarkers.
- Consistent benefit seen in subpopulation with Aβ pathology and ≥2 inflammatory biomarkers.
- Oral presentation at AAIC on July 29, 2025 at 2:00-3:30 PM ET in Toronto.
- Company seeking strategic partnership to accelerate XPro development for Alzheimer's.
- Publication of full results anticipated by mid-August 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025067791/0001213900-25-067791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025067791/ea0250327-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-067791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer